Health care resource utilization and cost of care for haemophilia A and B patients in Iran

Gharibnaseri, Zahra; Davari, Majid; Cheraghali, Abdol Majid; Eshghi, Peyman; Ravanbod, Roya; Espandar, Ramin; Hantooshzadeh, Razieh

doi:10.1016/j.transci.2016.01.025

Cited by 8 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be due to the high prices of clotting factor concentrates. In some other studies carried out on hemophilia A and B patients, including the studies by Gharibnaseri et al [9], Golestani et al [10] Cavazza et al [23] in European countries [23], Henrad et al in Belgium [6], and also in the study by Minno et al [24], medications and clotting factor concentrates accounted for the highest direct medical costs. Thus, the results of their studies are in line with those of the present research.…”

Section: Discussionmentioning

confidence: 99%

“…However, 50 vials are needed to prevent bleeding in case of a surgery or car accident and severe bleeding. According to the statistics by the World Federation of Hemophilia in 2015, the mean annual cost of healthcare services in Iran was 15130 USD per patient [9].…”

Section: Introductionmentioning

confidence: 99%

“…There are also some studies on hemophilia conducted in Iran. For instance, Golestani et al [10] found out that the costs of each bleeding therapy course with FEIBA (Factor Eight Inhibitor Bypassing Activity) and AryoSeven (Factor VII) per hemophilia A patient with a high antibody titer were respectively $ 376 and $ 857.3 in 2014 [9]. In their study, Gharibnaseri et al [9] indicated that in 2014, the mean annual cost of health care for a patient was $ 15130, the largest part of which (67%) accounted for medication.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Economic burden of hemophilia A and B: a case in Iran

et al. 2020

View full text Add to dashboard Cite

Objective: To estimate the economic burden of hemophilia A and B in the patients referred to the related referral hospital in the south of Iran in 2017. Methods: This cross-sectional study was a partial economic evaluation and a cost of illness study, carried out in 2017. All the patients with hemophilia A and B referred to the related hospital affiliated to Shiraz University of Medical Sciences in the south of Iran were included in the study (N = n = 253). A data collection form was used to collect the required data, including patients' direct and indirect costs. Results: The mean annual cost was 36028 USD. The mean costs per patient with hemophilia A and B were 37661 USD and 30775 USD, respectively, in which the greatest part were related to direct medical costs (98.32% in hemophilia A, 98.18% in hemophilia B, and 98.29% of the total costs), and the cost of clotting factor concentrates accounted for the largest share of the patients' direct medical costs. Also, considering the number of hemophilia patients in Iran, the mean annual cost of the patients in 2017 was 414480325 USD, of which 381503701 USD was for hemophilia A and 32976624 USD was for hemophilia B patients. Conclusion: Considering the significant economic burden of hemophilia and in order to reduce the costs, the following suggestions can be offered: provision of clotting factor concentrates domestically in accordance with the world standards, and providing specialized services and care to hemophilia patients in towns.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Economic burden of hemophilia A and B: a case in Iran

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The average annual health care cost for every patient was USD 15,130 in Iran in 2018, 67% of it referred to medication [6]. All factor concentrates (medications), diagnostic tests and other health care services of patients with hemophilia A (PWHA) in Iran are covered by the ministry of health and health insurance organizations so that all facilities are free for the patients [3].…”

Section: Introductionmentioning

confidence: 99%

“…In episodic therapy, any bleeding episode could be managed by the patients in their home [9]. As in the other developing countries, episodic therapy is the most common therapeutic strategy to manage the joint bleeding episodes in Iran [3,10].The most part of the medical costs of PWHA is because of FVIII consumption [6]. Hence, governments should pay more attention to utilize their resources to improve hemophilia' treatment.…”

Section: Introductionmentioning

confidence: 99%

Economic Analysis of an Ambulatory Care Service Delivery Model for Hemophilia a Patients; A Cost Minimization Study

Sadeghi

Davari

Gharibnaseri

et al. 2020

JPRI

Self Cite

View full text Add to dashboard Cite

Aim: This study aimed to perform an economic evaluation of Hemophilia ambulatory service delivery model (HASDM) comparing to the traditional home-episodic treatment model. Study Design: Tehran university of medical science, department pharmacoeconomics and pharmaceutical administration, between Jun 2016 and September 2018. Methods: A cost-minimization analysis (CMA) was conducted for evaluating potential savings of HASDM in comparison to the traditional home-episodic treatment model. The main cost of regular episodic service delivery, basic arm, consists of the cost of recombinant factor VIII (FVIII). In the comparator arm, HASDM, the costs of HASDM for 1660 hemophilia A patients (HAPs) in Tehran were calculated. One-way sensitivity analysis was done to investigate the robustness of the results and to investigate the impact of uncertainty in the percentage of mistakes in bleeding sensation. Results: There were 1660 patients with severe Hemophilia A (PWSHA) in Tehran in 2018. The mean utilization of annual per patient FVIII was 44814 international units (IUs) in Iran. The total annual cost of FVIII concentrate for 1660 hemophilic patients in Tehran was estimated at $ 11,001,816. The cost of running HASDM, personal, and equipment is equal to $ 580,956. The cost of FVIII in HASDM would be $ 4,004,661. Therefore, the total cost of HASDM is estimated at $ 4,585,617. The amount of savings was $ 6,416,199. Sensitivity analysis indicated the robustness of the results up to 94.64% of the variation in the model parameters. Conclusions: HASDM, compared to episodic model, can save 58.32% of the funding for controlling bleeding in HAPs annually. This can save more than 38 times of HAPs annual cost over their lifetime.

show abstract